Aegis Capital released a 2-3 page write-up on PYMX today.
They wrote an analyst report for Cubist. In ocvering their competition, they wrote an extremely long, extremely detailed description of the science and clinical trial data of 30063. Unusual to go into this much description of a competitor in an analyst report....in my opinion.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.